10-Q: BioRegenx Q1 2026 Financial Results and Going Concern

BioRegenx reports a net loss of $26,415 for Q1 2026 while highlighting substantial doubt regarding its ability to continue as a going concern due to defaults on $522,500 in debt.

Summary

• Net sales for the quarter ended March 31, 2026, were $426,175, a 17% decrease compared to $515,147 in the same period of 2025.
• Gross profit declined 14% to $348,288 from $406,031 in the prior year period.
• Net loss narrowed significantly to $26,415 from $266,854 in Q1 2025, aided by a $100,435 gain from other income and expense write-offs.
• The company reports a stockholders' deficit of $4,533,316 as of March 31, 2026.
• Cash on hand decreased to $45,806 from $69,383 at the end of 2025.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this as a high-risk situation due to the combination of recurring losses, significant debt defaults, and admitted material weaknesses in financial reporting controls.

Positives

• Operating expenses were reduced by 34% year-over-year, dropping from $598,646 to $398,052.
• Net loss improved by approximately 90% compared to the first quarter of 2025.
• The company successfully reduced its accounts payable to related parties from $355,747 to $257,248.

Negatives

• The company is in default on $522,500 of notes payable and loans.
• Management has concluded there is substantial doubt about the company's ability to continue as a going concern.
• Net sales declined 17% due to product issues with medical testing machines affecting nutritional sales.
• Internal controls over financial reporting were deemed ineffective due to material weaknesses, including insufficient qualified personnel and lack of segregation of duties.

Risks

• Substantial doubt regarding the company's ability to continue as a going concern.
• Default on $522,500 in debt obligations, which could lead to acceleration of payments.
• Dependence on future debt or equity financing to maintain operations.
• Potential for significant dilution of existing shareholders if equity financing is pursued.
• Ongoing legal disputes with former officers and affiliated entities.

Future Outlook

The company intends to raise additional debt or equity financing to fund ongoing operations and working capital, though management notes there is no assurance such financing will be available or on satisfactory terms.

Management Comments

• Management has concluded that there is substantial doubt about the company's ability to continue as a going concern.
• The company intends to pursue the action against former officers vigorously.
• Management is pursuing extensions and other arrangements to cure delinquencies and improve liquidity.

Industry Context

StockSavvy.ai notes that BioRegenx operates in a highly competitive medical and wellness space where consistent capital access is critical; the company's reliance on related-party funding and its inability to resolve debt defaults places it in a precarious position compared to healthier industry peers.

Comparison to Industry Standards

• The company's reliance on related-party loans for working capital is atypical for stable, publicly traded medical device firms.
• The presence of material weaknesses in internal controls is a significant deviation from the governance standards expected of SEC-reporting companies.
• The company's recurring losses and going concern status contrast sharply with established medical technology companies that typically maintain positive cash flows and robust balance sheets.

Corporate Governance

Legal Proceedings

• Ongoing litigation against former officers Bob Long and Hans Vink regarding intellectual property and breach of contract.
• Disputes with various vendors and former board members regarding contract performance and liabilities.

Related Party Transactions

• Rental of headquarters from BBD Holdings, LLC, controlled by director Joseph Bird.
• Significant outstanding debt and accrued interest owed to various trusts and individuals associated with current or former officers.
• Reimbursement of company expenses to CEO William Resides and other board members.

Stakeholder Impact

• Shareholders face significant risk of dilution if the company issues equity to raise capital.
• Creditors are impacted by the company's default on $522,500 in debt.
• Employees and contractors are affected by the company's limited liquidity and ongoing financial instability.

Next Steps

• Continue pursuing financing alternatives to support operations.
• Attempt to cure debt delinquencies through extensions or other arrangements.
• Continue legal action against former officers and affiliated entities.
• Remediate identified material weaknesses in internal control over financial reporting.

Key Dates

Recommendation

The combination of a going concern warning, significant debt defaults, declining revenue, and material weaknesses in financial controls makes this an extremely high-risk investment that does not meet the criteria for a stable or growth-oriented portfolio.

Keywords

BioRegenx, BRGX, Medical Testing, Nutraceuticals, Going Concern, Debt Default, 10-Q